EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 183 filers reported holding EAGLE PHARMACEUTICALS INC in Q4 2018. The put-call ratio across all filers is 1.51 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2019 | $405,000 | -39.7% | 6,746 | -43.2% | 0.01% | -37.5% |
| Q3 2019 | $672,000 | -24.5% | 11,878 | -25.7% | 0.01% | -20.0% |
| Q2 2019 | $890,000 | +10.8% | 15,983 | +0.6% | 0.01% | 0.0% |
| Q1 2019 | $803,000 | +17.7% | 15,895 | -6.2% | 0.01% | +11.1% |
| Q4 2018 | $682,000 | -39.2% | 16,937 | +4.8% | 0.01% | -18.2% |
| Q3 2018 | $1,121,000 | +22.5% | 16,162 | +33.7% | 0.01% | +22.2% |
| Q2 2018 | $915,000 | +32.0% | 12,091 | -8.0% | 0.01% | +28.6% |
| Q1 2018 | $693,000 | -7.6% | 13,144 | -6.4% | 0.01% | 0.0% |
| Q4 2017 | $750,000 | +186.3% | 14,044 | +219.2% | 0.01% | +133.3% |
| Q3 2017 | $262,000 | -18.9% | 4,400 | +7.3% | 0.00% | -25.0% |
| Q2 2017 | $323,000 | -7.2% | 4,100 | -2.4% | 0.00% | -20.0% |
| Q1 2017 | $348,000 | +7.1% | 4,200 | +2.4% | 0.01% | 0.0% |
| Q4 2016 | $325,000 | +13.2% | 4,100 | 0.0% | 0.01% | +25.0% |
| Q3 2016 | $287,000 | – | 4,100 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |